科笛(2487.HK):CU-10201III期临床试验的事后分析在第二十届CDA年会口头发言

IR之家
Nov 10

科笛公司董事会宣布,集团CU-10201治疗中度至重度面部寻常痤疮的早期疗效的一项中华人民共和国III期临床试验的事后分析被选为在第二十届中国医师协会皮肤科医师年会暨全国美容皮肤科学大会上口头发言。CU-10201是全球首个且唯一一个获批用于寻常痤疮治疗的外用米诺环素,也是首个获得中国国家药品监督管理局优先审评审批资格批准上市的外用米诺环素。CU-10201针对中国中度至重度寻常痤疮患者的12周...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10